JavaScript is disabled. Please enable to continue!
Our Services >> Biomarker Analysis >> Biomarker measurement

Biomarker measurement

Sidebar Image

long with the other team members of the Eurofins Group we at Eurofins Medigenomix aim for best service in biomarker business to fulfill your needs and requirements, flexible, fast and reliable - today and in the future. We develop biomarker solutions tailored to your needs and take over comprehensive tasks in the areas of genetic and genomic biomarker analysis. We provide you with competent and comprehensive advice to find the best solution for each biomarker project in planning at any time. We vouch for highest quality with automated analytical methods, high capacities as well as standardized and highly efficient process flows.

Genetic and Genomic Biomarker Analysis

Eurofins Medigenomix has many years of extensive experience in the application of different methods and technologies in the field of genetics and genomics. We offer a broad spectrum of genetic and genomic biomarker analysis, which are crucial for the entire drug development process, starting from the preclinical phase through all phases of clinical trials (phases I, II and III). Both single samples as well as batches of several thousand samples can be processed. Genetic and genomic biomarker analysis can be performed based on different sample material. For example, we offer genotyping in the scope of clinical trials, according to the principles of Good Laboratory Practice (GLP) and in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice (GCP). Using state-of-the-art technologies like sequencing, mass spectrometry (MALDI) and Real Time PCR defined alleles and their underlying genetic polymorphisms of target genes can be analyzed (genotyping). Besides analysis of pharmacogenetic relevant genes, Eurofins Medigenomix offers also analysis of target genes which play an important role in clinical diagnostics.

The genetic biomarker assay portfolio of Eurofins Medigenomix covers amongst others analysis for the following pharmacogenetic relevant genes:

  • Drug metabolizing enzymes, DMEs (Phase I enzymes/Cytochrome P450 enzymes, Phase II enzymes)
  • Drug transporters (Solute Carrier (SLC)- and ATP Binding Cassette (ABC)-transporters)
  • Drug receptors e.g. G-protein coupled receptors (GPCRs)
  • G-proteins e.g. GNAS1 or GNB3

Service Policy

According to our service policy, we actively support all our customers in defining the questions which are important for their biomarker project, enabling the customer to achieve his project objectives in a quick, reliable and cost efficient way. Based on verified scientific data we develop an appropriate strategy for the different questions of the customer's biomarker project. At the end of this assessment of requirements the most suitable, project-specific biomarker analysis technology will be available.

Please contact us to discuss your project or your study in